Annals of Medicine & Surgery
Before the bolus: why anti-amyloid therapy must become part of every stroke code
Anti-amyloid monoclonal antibodies provide disease-modifying treatment options for selected patients with early symptomatic Alzheimer disease, but introduce new challenges for acute stroke care. Amyloid-related imaging abnormalities (ARIA) are often asymptomatic; however, symptomatic ARIA may cause aphasia, focal weakness, visual disturbance, confusion, headache, or seizures, and can resemble acute ischemic stroke. Initial noncontrast computed tomography may be nondiagnostic in both conditions, and failure to ident …